According to Kotak Institutional Equities, Mankind Pharma’s base domestic business is finally showing tangible signs of recovery after a prolonged restructuring impact, thereby becoming one of the key reasons behind its upgrade for the stock.
According to Kotak Institutional Equities, Mankind Pharma’s base domestic business is finally showing tangible signs of recovery after a prolonged restructuring impact, thereby becoming one of the key reasons behind its upgrade for the stock.